INTRODUCTION
Recently, efforts by researchers involved in the development of anti-tumor drugs have focused on targeted therapeutic agents based both on novel and already-known cytostatic drugs [1] . The use of nanocontainers (liposomes, micelles, polymer nanoparticles, virus-like particles, and viruses) modified with specific ligands filled with a drug is considered the most efficient delivery method [2] . However, these innovative delivery methods do not solve the problem of cancer multidrug resistance, which has the potential to undermine all previous efforts to enhance drug efficacy [3] .
It has been demonstrated that Tl + ions exhibit strong cytotoxic activity and inhibit the cancer drug resistance-associated protein that acts as an efflux pump [4] . Incorporation of Tl + into a "non-leaking" nanosized container equipped with a targeted delivery system could allow one to develop an efficient tool for tumor destruction, while the overall toxicity of Tl + can be significantly mitigated. In the 1980s, Tl + ions were successfully entrapped in cowpox virus particles [5] . The entrapment mechanism involved the formation of a strong conjugate between Tl + and viral RNA [6] . The bacteriophage MS2 selected as a nanocontainer can reproduce itself only in Escherichia coli cells that carry F-pili and are neither human symbionts nor pathogens [7] . The delivery direction was ensured via conjugation of phage capsid proteins and the (Gly) 3 -iRGD peptide carrying the cycloSS-(CRGDKGPDC) (iRGD) moiety, which is responsible for binding to integrins that predominantly localize on the outer membranes of endothelial cells of the pathological neovasculature of solid tumors and on a number of tumor cells [8] . In this study, we experimentally tested the effectiveness of Tl + -filled bacteriophage MS2 carrying a targeting peptide as a candidate antitumor agent.
EXPERIMENTAL
The procedure used to prepare bacteriophage MS2 was described earlier in [9] . The number of plaque-forming units (PFUs) per milliliter of the phage preparation was identified by agar overlay assay.
(Gly)3-iRGD peptide was prepared by automated solid-phase synthesis using 9-fluorenylmethoxycarbonyl amino acids (ChemPep, USA) on a 433A peptide synthesizer (Applied Biosystems) through the FastMoc method. The S-S bridge was formed by oxidation with I 2 [10] . The peptide was purified by reversed-phase HPLC (YMC-Triart C18 column, 21 × 250 mm, 10.0 µm, Switzerland; Agilent 1100 working station, Agilent, USA), elution by CH 3 CN (BioSolve, Israel) concentration gradient in water containing 0.1% acetic acid. According to the data obtained by analytical reversedphase HPLC (YMC-Triart C18 column, 2.1 × 50 mm, 2.0 µm, Agilent 1200 working station) with UV and mass-spectrometry detection, purity of the peptide preparation was ≥ 95%.
(Gly) 3 -iRGD peptide was conjugated to bacteriophage MS2 capsid proteins using a homobifunctional reagent dimethyl adipimidate (DMAI, Sigma, USA) at a phage protein : peptide : DMAI molar ratio of 1 : 20 : 80, using the procedure described in [11] . The bacteriophage was separated from the excess reagents via precipitation with a 25% polyethylene glycol 6000 solution (Dia-M, Russia) containing 1 M NaCl. The precipitated bacteriophage was suspended in deionized water.
The bacteriophage was filled with Tl + using TlNO 3 (Sigma-Aldrich, USA). The peptide-conjugated bacteriophage MS2 (iRGD-MS2) (10 11 PFUs) was incubated in 3 ml of a 0.5 µM TlNO 3 solution (5 h at 38°C), followed by precipitation according to the procedure described above and dialysis against phosphate buffered saline (0.14 M NaCl, 0.01 M sodium phosphate, pH 7.4).
The amounts of Tl + ions both inside and outside the virions (in the medium) were determined using the procedure described in [12] . A suspension of bacteriophage particles filled with Tl + was centrifuged for 10 min at 5,000 rpm to remove the thallium salt precipitate, diluted with 50 mM Tris-HCl buffer (pH 9.0) until a nominal concentration of 10 8 PFUs/ml, and denatured by heating with RNase in 0.05% SDS at +70°C for 30 min. Quenching of 1,3,6,8-pyrene tetrasulfonic acid fluorescence by Tl + ions was then recorded (excitation wavelength, 340 nm; emission wavelength, 465 nm) on an UV-1900 spectrofluorometer (BOC Sciences APP, USA). A calibration curve showing the dependence between the fluorescence quenching degree and [Tl + ] was used to calculate the content of Tl in the bacteriophage preparation. The Tl content in the buffer solution after dialysis was determined without pre-denaturation.
The cytotoxic effect of iRGD-MS2-Tl + on the cell cultures was studied using MCF-7 (hormone-dependent breast cancer) and MDA-MB-231 (hormoneindependent breast cancer) cell lines. The cells were cultured in a serum-free medium (MSC1 Pan BioTech) and in the same medium supplemented with 5% fetal calf serum. The iRGD-MS2-Tl + preparation was added in 10-fold dilutions, starting with a concentration of 10 8 PFU/ml. The iRGD-MS2 preparation (the peptide-conjugated bacteriophage without Tl + ) was used as a control. Dead cells were counted after staining with Evans blue. The antitumor effect of the iRGD-MS2-Tl + preparation was tested in nude mice with MCF-7 or MDA-MB-231 cancer cell-derived xenografts. The mice were injected with 10 5 -10 6 MCF-7 or MDA-MB-231 cells intradermally. Fourteen days later, the mice in the experimental groups received 200 µl of a suspension containing iRGD-MS2-Tl + at a dose corresponding to 10 8 PFU/kg intraperitoneally during 10 days (once per day). Mice in the control group were injected with iRGD-MS2, MS2-Tl + , or MS2-Tl + + iRGD (2 µg/kg in solution) of the MS2 dosage equal to the iRGD-MS2-Tl + doses for experimental animals, and in the same volume of the solution. Each experimental and control group consisted of 11 animals. The necrotic activity of the preparation was determined as a ratio between the area of necrosis tissue and the total area of the tumor by analyzing digital images of histologic sections recorded using a ScanScope CS2 scanner 12 days after the last injection of bacteriophage preparations.
Acute toxicity of the iRGD-MS2-Tl + preparation was preliminarily studied on 10 female Wistar Kyoto (WKY) rats (weight, 200-250 g). The rats were housed under the conditions of 12-hour light and 12-hour dark cycle and given ad libitum access to a standard laboratory diet and water. The animals received a single intradermal injection of the preparation (10 8 PFU/animal, 500 µl). 
Figure 1 demonstrates that the iRGD-MS2-Tl
+ preparation had a cytotoxic effect on hormone-dependent and hormone-independent breast cancer cells in the serum-free medium. For hormone-dependent BC (MCF-7 cells), ED 50 of the iRGD-MS2-Tl + preparation was slightly lower than 10 5 PFU/ml of the culture broth, while the cytotoxic effect of the preparation was statistically significant compared to the control specimen, up to a concentration of 10 PFU/ml. Hormoneindependent breast cancer (MDA-MB-231) cells were more resistant to the preparation: for these cells, ЕD 50 in a serum-free medium was 10 6 -10 7 PFU/ml, while the cytotoxic effect of the preparation was statistically significant compared to the control specimen, up to a concentration of 10 4 PFU/ml. The cytotoxic activity of iRGD-MS2-Tl + was much weaker in the serum-containing medium, which may be an indication that serum components and iRGD-MS2-Tl + particles compete for penetration into the cells.
In mice with MCF-7 and MDA-MB-231 xenografts, the tumor volume was reduced 12 days following the injections of the iRGD-MS2-Tl + preparation compared to that in the control animals (Fig. 2) . The necrotizing effect of iRGD-MS2-Tl + on the corresponding tumors was demonstrated histochemically. Figure 3 shows that the iRGD-MS2-Tl + preparation was more efficient in causing tumor tissue necrosis (p < 0.05) than peptide-conjugated phage preparations without Tl 
CONCLUSIONS
Targeted delivery of ions of a toxic metal to a tumor neovasculature using phage display based on iRGD-MS2-Tl + particles causes efficient degradation of the entire tumor mass, while the risk of overall toxicity is significantly reduced. Therefore, it is reasonable to recommend conducting preclinical trials of iRGD-MS2-Tl + in order to develop a preparation which can potentially be further used to treat breast cancer. Since the iRGD peptide ligand interacts with a ν b 3 and a ν b 5 integrins on the surface of endothelial cells in the pathological vasculature [8] , this drug may be efficient against other solid tumors characterized by intensive pathological neoangiogenesis.
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